Levoatriocardinal vein (LACV) is characterized by an abnormal connection between pulmonary and systemic venous return. This extremely rare cardiac malformation is usually associated with left-sided obstructive lesions including mitral atresia, hypoplastic left-heart syndrome, and abnormal pulmonary venous connection. Patients may have low systemic cardiac output and pulmonary venous obstruction symptoms. In this manuscript, we report a case with LACV and normal pulmonary venous return with absence of any intracardiac pathology. LACV was demonstrated with echocardiography, angiography, and computed tomography. Surgical correction was made successfully.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180981 | PMC |
| http://dx.doi.org/10.4103/0974-2069.84667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Outcome Following Concomitant Surgical Ablation for Atrial Fibrillation at University Hospital Basel: A Retrospective Study.
Medicina (Kaunas)
December 2024
Heart Center Hirslanden Zurich, 8008 Zurich, Switzerland.
: This study aims to examine the success of concomitant surgical ablation in patients with atrial fibrillation after one, three, and five years. Additionally, important predictors for rhythm outcome and rates of permanent pacemaker implantations were analyzed. : In this retrospective study, we included patients who were referred to the University Hospital of Basel, Switzerland, between 2011 and 2017.
View Article and Find Full Text PDFDevelopment of a Predictive Model of Occult Cancer After a Venous Thromboembolism Event Using Machine Learning: The CLOVER Study.
Medicina (Kaunas)
December 2024
Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.
: Venous thromboembolism (VTE) can be the first manifestation of an underlying cancer. This study aimed to develop a predictive model to assess the risk of occult cancer between 30 days and 24 months after a venous thrombotic event using machine learning (ML). : We designed a case-control study nested in a cohort of patients with VTE included in a prospective registry from two Spanish hospitals between 2005 and 2021.
View Article and Find Full Text PDFTherapeutic Drug Monitoring of Vancomycin in Hemodialysis Patients in a Hospital in North-East Romania.
Antibiotics (Basel)
January 2025
Department of Morpho-Functional Sciences II-Pharmacology, Clinical Pharmacology and Algeziology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania.
: Vancomycin is a reserve antibiotic that is frequently prescribed for central venous catheter (CVC)-associated infections in hemodialysis patients. Hemodialysis patients are very fragile patients and the presence of CVCs increases the risk of sepsis. We conducted a prospective study, evaluating the needs of changes in vancomycin dosing for treatment based on the use of the new 2020 vancomycin dosing guidelines, to increase drug safety (preventing subtherapeutic or supratherapeutic doses and offering therapeutic concentrations of the drug) in a particular group of patients with sepsis caused by catheter infections and being on intermittent hemodialysis.
View Article and Find Full Text PDFPrevention and Treatment of Venous Thromboembolism Associated with Amivantamab-Based Therapies in Patients with Lung Cancer-Provisional Clinical Opinion Based on Existing Clinical Practice Guidelines.
Cancers (Basel)
January 2025
Department of Medicine I, Division of Haematology & Haemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Improved efficacy has been shown for amivantamab and amivantamab-based combination therapies in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) compared to established treatment options in clinical trials. However, a high risk of venous thromboembolism (VTE) was observed in patients treated with amivantamab-based therapies, with considerable differences in VTE risk according to the line of systemic treatment, concomitant treatment with lazertinib, and intravenous vs. subcutaneous amivantamab administration.
View Article and Find Full Text PDFVenous Thromboembolism in Patients with Neuroendocrine Neoplasms: A Systematic Review of Incidence, Types, and Clinical Outcomes.
Cancers (Basel)
January 2025
Faculty of Medicine and Surgery Via Olgettina, Vita e Salute San Raffaele University, 56, 20132 Milan, Italy.
: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with unique biological characteristics and complications, including thromboembolism. This systematic review evaluates the incidence, types, and clinical outcomes of venous thromboembolic events (VTEs) in NEN patients. : A systematic search of PubMed, Scopus, and Embase was conducted to identify studies on TEs in NENs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!